## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $110 | $85 | +29% |
| 2025-11-17 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-12 | Guggenheim | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-17 | Canaccord Genui | main | Buy |
| 2025-11-12 | Guggenheim | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.58) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-8.8% 5d) with bearish MACD, trend may be turning.
3. High short interest (15.6%, 4.5 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Analyst sentiment positive (2 raises, avg +26%). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 1.00 |
| 52W Range | $16.10 - $115.76 |
| Short Interest | 15.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 5.5% to -3.3% (-8.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.94x) but short-term weakness (below SMA20). MACD histogram bearish (-1.50), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.30% (CS: 21) | Weak |
| RSI_14 | 51.6 | Neutral |
| MACD Histogram | -1.50 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.943x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $95.06
- **Stop Loss:** $79.64 (16.2% risk)
- **Target:** $110.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $8,460.34
- **Portfolio %:** 8.46%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*